Market Cap 46.82M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,815,140
Avg Vol 10,939,872
Day's Range N/A - N/A
Shares Out 69.34M
Stochastic %K 91%
Beta -0.08
Analysts Strong Sell
Price Target $6.25

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408-501-8881
Fax: 408-904-6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
Szeinaru
Szeinaru Oct. 27 at 6:42 PM
$RVPH took a quick 150 profit on my new budget using $ASST hoping this falls a bit more so I can invest extra at .55
0 · Reply
MTN52C
MTN52C Oct. 27 at 6:20 PM
$RVPH this is not an if it's a when. Full on accumulation for me until then. If theres news of rs i'm porting out and sizing up my shares on the bottom, but for now it seems we are good until May 2026 which is more than enough to get this going to $1+ if nda meeting is positive in November-December
0 · Reply
Stockboi_
Stockboi_ Oct. 27 at 6:07 PM
$RVPH support needs to hold here. Weekly is still strong
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:57 PM
$RVPH RVPH: - Marketcap $65 million with approximately 96 million shares Second quarter reporting June 30 2025: - $113,246 in debt (low debt). This represents a significant decrease from the $458,154 in debt it reported at the end of 2024. - Total Assets: $11,630,000 - Total Liabilities: $12,093,993 - Cash on hand: $10,363,714 - Additional cash: $9 million public offering September 2025
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:57 PM
$RVPH What is Brilaroxazine: - Brilaroxazine (RP5063) is an investigational drug being developed as a novel, third-generation antipsychotic for the treatment of schizophrenia. It is also being studied for other neuropsychiatric and neurological conditions, and preliminary clinical trial data have shown it can improve symptoms with a potentially favorable safety profile regarding weight gain, glucose, and lipid levels compared to other antipsychotics.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:56 PM
$RVPH - Brilaroxazine is unique due to its novel, multimodal mechanism that targets serotonin and dopamine systems to potentially improve efficacy and side effect profiles, with a key difference being its potent action on the 5-HT2B receptor. This specific receptor interaction is thought to help manage neuroinflammation, which could address negative and depressive symptoms, as well as cognitive issues, that current treatments struggle with. Furthermore, preliminary data suggests a favorable side effect profile, with minimal impact on movement disorders, weight gain, and other common adverse effects associated with older antipsychotics.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:55 PM
$RVPH - Serotonin and dopamine modulation:Unlike older drugs that focus primarily on D2 and 5-HT2A receptors, brilaroxazine is a partial agonist at D2, D3, D4, and 5-HT1A receptors, and also has potent antagonistic activity at 5-HT2B and 5-HT7 receptors. - Targeting neuroinflammation: Its potent activity on the 5-HT2B receptor is significant because this receptor is highly expressed in the brain and is implicated in neuroinflammation, which is a driver of schizophrenia symptoms. By modulating this receptor, brilaroxazine may offer benefits beyond symptom control.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:54 PM
$RVPH - Reduced motor side effects: Clinical trial data suggests brilaroxazine has minimal or no activity on targets known to cause motor side effects like akathisia and extrapyramidal symptoms. - Lower impact on weight gain: One study reported no significant weight gain in patients taking brilaroxazine. Other sources note a lack of drug-related serious adverse events and minimal weight gain in one-year studies. - Other benefits: Brilaroxazine also shows promise in addressing symptoms that are difficult to treat with current medications, such as negative symptoms, depressive symptoms, and cognitive impairment. - Brilaroxazine is generally a well-tolerated antipsychotic medication with a favorable safety profile. The most common side effects are mild and transient.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:53 PM
$RVPH Catalysts: - Brilaroxazine has completed phase 3 clinical trials for Schizophrenia. - Reviva is planning a meeting with the FDA in late 2025 to discuss the path to approval and could submit its New Drug Application (NDA) in the second quarter of 2026 brilaroxazine's use in schizophrenia. - Market launch after FDA approval
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:53 PM
$RVPH Why RVPH is undervalued: Reviva Pharmaceuticals owns brilaroxazine and holds several patents on it, including the composition of matter patents for the compound itself and patents for its use in treating conditions like pulmonary fibrosis pulmonary hypertension and schizophrenia. The company discovered brilaroxazine in-house, and its intellectual property for the drug has been granted in countries including the United States, Europe, China, Japan, and Canada. Around 24 million people world wide is diagnosed with Schizophrenia. - United States: 3.7 million people - Europe: 4 million people - China: 5.3 million people - Japan: 1.9 million people
0 · Reply
Latest News on RVPH
Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 5 weeks ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX


Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 9 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference


Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 11 months ago

Reviva Announces Proposed Public Offering


Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference


Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention


Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day


Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference


Reviva Pharma's schizophrenia drug succeeds in late-stage study

Oct 30, 2023, 7:41 AM EDT - 2 years ago

Reviva Pharma's schizophrenia drug succeeds in late-stage study


Szeinaru
Szeinaru Oct. 27 at 6:42 PM
$RVPH took a quick 150 profit on my new budget using $ASST hoping this falls a bit more so I can invest extra at .55
0 · Reply
MTN52C
MTN52C Oct. 27 at 6:20 PM
$RVPH this is not an if it's a when. Full on accumulation for me until then. If theres news of rs i'm porting out and sizing up my shares on the bottom, but for now it seems we are good until May 2026 which is more than enough to get this going to $1+ if nda meeting is positive in November-December
0 · Reply
Stockboi_
Stockboi_ Oct. 27 at 6:07 PM
$RVPH support needs to hold here. Weekly is still strong
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:57 PM
$RVPH RVPH: - Marketcap $65 million with approximately 96 million shares Second quarter reporting June 30 2025: - $113,246 in debt (low debt). This represents a significant decrease from the $458,154 in debt it reported at the end of 2024. - Total Assets: $11,630,000 - Total Liabilities: $12,093,993 - Cash on hand: $10,363,714 - Additional cash: $9 million public offering September 2025
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:57 PM
$RVPH What is Brilaroxazine: - Brilaroxazine (RP5063) is an investigational drug being developed as a novel, third-generation antipsychotic for the treatment of schizophrenia. It is also being studied for other neuropsychiatric and neurological conditions, and preliminary clinical trial data have shown it can improve symptoms with a potentially favorable safety profile regarding weight gain, glucose, and lipid levels compared to other antipsychotics.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:56 PM
$RVPH - Brilaroxazine is unique due to its novel, multimodal mechanism that targets serotonin and dopamine systems to potentially improve efficacy and side effect profiles, with a key difference being its potent action on the 5-HT2B receptor. This specific receptor interaction is thought to help manage neuroinflammation, which could address negative and depressive symptoms, as well as cognitive issues, that current treatments struggle with. Furthermore, preliminary data suggests a favorable side effect profile, with minimal impact on movement disorders, weight gain, and other common adverse effects associated with older antipsychotics.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:55 PM
$RVPH - Serotonin and dopamine modulation:Unlike older drugs that focus primarily on D2 and 5-HT2A receptors, brilaroxazine is a partial agonist at D2, D3, D4, and 5-HT1A receptors, and also has potent antagonistic activity at 5-HT2B and 5-HT7 receptors. - Targeting neuroinflammation: Its potent activity on the 5-HT2B receptor is significant because this receptor is highly expressed in the brain and is implicated in neuroinflammation, which is a driver of schizophrenia symptoms. By modulating this receptor, brilaroxazine may offer benefits beyond symptom control.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:54 PM
$RVPH - Reduced motor side effects: Clinical trial data suggests brilaroxazine has minimal or no activity on targets known to cause motor side effects like akathisia and extrapyramidal symptoms. - Lower impact on weight gain: One study reported no significant weight gain in patients taking brilaroxazine. Other sources note a lack of drug-related serious adverse events and minimal weight gain in one-year studies. - Other benefits: Brilaroxazine also shows promise in addressing symptoms that are difficult to treat with current medications, such as negative symptoms, depressive symptoms, and cognitive impairment. - Brilaroxazine is generally a well-tolerated antipsychotic medication with a favorable safety profile. The most common side effects are mild and transient.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:53 PM
$RVPH Catalysts: - Brilaroxazine has completed phase 3 clinical trials for Schizophrenia. - Reviva is planning a meeting with the FDA in late 2025 to discuss the path to approval and could submit its New Drug Application (NDA) in the second quarter of 2026 brilaroxazine's use in schizophrenia. - Market launch after FDA approval
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:53 PM
$RVPH Why RVPH is undervalued: Reviva Pharmaceuticals owns brilaroxazine and holds several patents on it, including the composition of matter patents for the compound itself and patents for its use in treating conditions like pulmonary fibrosis pulmonary hypertension and schizophrenia. The company discovered brilaroxazine in-house, and its intellectual property for the drug has been granted in countries including the United States, Europe, China, Japan, and Canada. Around 24 million people world wide is diagnosed with Schizophrenia. - United States: 3.7 million people - Europe: 4 million people - China: 5.3 million people - Japan: 1.9 million people
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:52 PM
$RVPH - Reviva Pharmaceuticals Holdings, Inc. (RVPH) is planning to market Brilaroxazine in the United States, Europe, China, and Japan. - Brand name schizophrenia medications vary widely in price, with a 30-day supply potentially costing anywhere from around $190 to over $1.X,400 - The U.S. schizophrenia market was approximately $2.X.84 billion in 2024 and is projected to grow to $12.78 billion by 2032 - Brilaroxazine is being developed as a brand-name drug. Reviva Pharmaceuticals anticipates having exclusivity for Brilaroxazine until around 2045 - Reviva has stated its intent to develop brilaroxazine for other neuropsychiatric conditions beyond schizophrenia, including bipolar disorder, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD). - Inflammatory and cardiometabolic diseases: The company is also exploring the drug's potential in treating conditions such as psoriasis, pulmonary arterial hypertension (PAH), and idiopathic pulmonary fibrosis (IPF).
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:52 PM
$RVPH - Orphan Drug Designations: Brilaroxazine has received Orphan Drug Designation from the U.S. FDA for both PAH and IPF, which may fast-track its development and provide marketing exclusivity for those conditions if approved. - Granted patents: Reviva has been granted U.S. and European patents covering the use of brilaroxazine for treating pulmonary hypertension and idiopathic pulmonary fibrosis, providing protection for those uses. - This broad development strategy indicates that Reviva is setting itself up to earn revenue from brilaroxazine in multiple treatment areas, not just schizophrenia
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:49 PM
$RVPH Lets say approximately 14,900,000 people within these Countries (US, China, Europe and Japan) RVPH is targeting for Brilaroxazine. If 10% of these people decide to use Brilaroxazine that's 1,490,000 people x $190-500 = $238-745 million monthly revenue. That's 3.3-9 billion revenue annualy. These numbers are low ball park numbers. If Brilaroxazine is favored due to their safety profile and efficiency, they would perhaps dominate the market as a prefered choice for schizophrenia. In addition to the other conditions RVPH is planning to cater to beyond schizophrenia. RVPH is extremely undervalued and can 100x+ into a marketcap suited by their accumulated revenue once Brilaroxazine start to scale.
0 · Reply
MTN52C
MTN52C Oct. 27 at 5:47 PM
$RVPH i'm in 81,500 shares. planning to buy another 37,000 tomorrow and monthly average down $3000/monthly. Until fda meeting
0 · Reply
ERPBlast
ERPBlast Oct. 27 at 5:12 PM
$RVPH nothing?
0 · Reply
Stockboi_
Stockboi_ Oct. 27 at 4:24 PM
$RVPH added
0 · Reply
GibsonFlyingV
GibsonFlyingV Oct. 27 at 3:46 PM
$RVPH little by little is the game we play. Bought more this morning on the dip just below 0.60
0 · Reply
KingPurcy
KingPurcy Oct. 27 at 3:38 PM
$AREB $INHD $RVPH $YYAI each one of these should be $5-$8 at least by eoy
1 · Reply
MTN52C
MTN52C Oct. 27 at 3:37 PM
$RVPH fk it i'm buying and accumulating RVPH is a forsure riser
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 27 at 3:04 PM
$RVPH In order for a short squeeze to happen- we would need over 60M-70M shares to trade.
0 · Reply
ERPBlast
ERPBlast Oct. 27 at 2:51 PM
$RVPH short squize?
0 · Reply
Bigtradesbigprofit
Bigtradesbigprofit Oct. 27 at 2:38 PM
$RVPH bought some $1 calls this morning
0 · Reply